drugset / Trial / NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Completed
500 enrolled
Stanford University
Amgen · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-label
Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Timeline
- Start
- 2000-11
- Primary completion
- 2007-06
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epratuzumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |